Reaction profile

The FDA adverse-event record for adenocarcinoma nos

Name: Adenocarcinoma NOS - FDA Animal Adverse Reaction
Creator: PlainBreed
License: https://open.fda.gov/license/

22 FDA reports name adenocarcinoma nos, a lower-volume reaction in the CVM extract (VeDDRA 2352). Plate stamps and neighbourhood peers follow.

#2121 of 2,481
by report volume (all reactions): 22
reports citing this reaction: 54.5%
death-coded share: Dog
most-affected species

Compiled by PlainBreed

Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Adenocarcinoma NOS has 22 reports now versus 21 in that prior snapshot: 1 more (4.8%).

Report change: +1
Death-coded reports: +0
Death-coded share: −2.6 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Adenocarcinoma NOS changes

FDA AER · VeDDRA plate

Code 2352 VOL-TRACE

VOL-TRACE · DEATH-HOT · LOWER-Q · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

VOL-TRACE 22 reports
DEATH-HOT 54.5%
LOWER-Q #2121/2481
PHOTO-FINISH Bolus, Abnormal
SPECIES-DOG Dog · 13
DRUG-LEAD Oclacitinib Malea… · 6
DESK-WIDE 18 breeds
BOOK-FULL 8/8 fields

Nearest volume peer: Bolus, Abnormal (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Lower-volume neighbourhood around Adenocarcinoma NOS

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

FDA AER report volume · neighbourhood around Adenocarcinoma NOS

Adenocarcinoma NOS: high death-coded share in the FDA AER plate

Signature read: Adenocarcinoma NOS's 54.5% death-coded share is among the highest in the openFDA reaction corpus. Report volume is lower-third scale: 22 named reports in the openFDA extract. Death-coded share is upper-third: 12 of 22 reports (54.5% of named reports). Nearest volume peer: Bolus, Abnormal (±0 reports). Lead species Dog (13). Lead co-reported drug Oclacitinib Maleate (6).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 13

Cat 5

Ferret 2

Parrot 2

Breeds Most Affected

Terrier (unspecified) 2

Retriever - Labrador 2

Parrot (other) 2

Domestic Shorthair 2

Terrier - Boston 1

Shepherd (unspecified) 1

American Shorthair 1

Great Pyrenees 1

Poodle - Standard 1

Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1

Associated Drugs

Oclacitinib Maleate 6

Meloxicam 6

Bedinvetmab 5

Gabapentin 4

Frunevetmab 4

Buprenorphine 3

Cyclosporine 2

Adequan 2

Robenacoxib 2

Enrofloxacin 2

Cephalexin 2

Tramadol 2

Sucralfate 2

Famotidine 2

Ciprofloxacin 2

Fluconazole 2

Famciclovir 2

Piperacillin/Tazobactam 2

Butorphanol 2

Trilostane 1

What to do with this reaction

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full reaction directory to compare report counts across reaction types. All reactions

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Adenocarcinoma NOS (#2121 of 2,481 by report volume); death-coded 54.5%. PlainBreed reaction plate · death-coded share stamp 54.5% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →